UroToday23h
ASCO 2021: Immunogenic Priming with 177Lu-PSMA-617 Plus Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: A phase 1b study
(UroToday.com) There has been a proliferation in treatment options for patients with metastatic castration resistant prostate cancer (mCRPC) in the last 10 years. While the most commonly utilized ...
UroToday1d
ASTRO 2024: Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: Feasibility, Safety, and Toxicity
The 2024 ASTRO annual meeting included a session on prostate cancer, featuring a presentation by Dr. LaToya McLean discussing feasibility, safety, and toxicity of hyaluronic acid rectal spacer in ...
UroToday1d
ASTRO 2024: MRI-Guided versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial
(UroToday.com) The 2024 ASTRO annual meeting included a session on optimizing the therapeutic ratio in prostate cancer, featuring a presentation by Dr. Amar Kishan discussing two-year outcomes from ...
UroToday2d
ASTRO 2024: Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer
(UroToday.com) The 2024 ASTRO annual meeting included a session on optimizing the therapeutic ratio in prostate cancer, featuring a presentation by Dr. Carlton Johnny discussing focal MR-guided HDR ...
UroToday2d
CLARIFY Trial Videos
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially ...
UroToday2d
ASTRO 2024 Featuring Validation of Digital Pathology MMAI Algorithm and of the Decipher® Genomic Testing in the VANDAAM Study
Yang Song presented findings on the ArteraAI Prostate Test, a digital pathology multimodal artificial intelligence (MMAI) algorithm, which was shown to predict overall survival in patients with ...
UroToday3d
ASTRO 2024: A Digital Pathology MMAI Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer
(UroToday.com) The 2024 ASTRO annual meeting included a session on novel prognostic tools in prostate cancer, featuring a presentation by Dr. Yang Song discussing the association with a digital ...
UroToday4d
2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach
The Dutch Urological Association (NVU) has revised its guidelines for the treatment of urinary incontinence (UI) in secondary and tertiary care, updating the 2014 guidelines to address specific ...
UroToday4d
Does the Extent of Transurethral Resection after Radiation Therapy Impact Survival Outcomes in Muscle-Invasive Bladder Cancer - Expert Commentary
A current standard of care treatment for muscle-invasive bladder cancer (MIBC) is platinum-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Bladder-sparing protocols are ...
UroToday4d
Integrated multi-omics assessment of lineage plasticity in a prostate cancer patient with brain and dural metastases.
Metastases to the brain are rare in prostate cancer. Here, we describe a patient with two treatment-emergent metastatic lesions, one to the brain with neuroendocrine prostate cancer (NEPC) histology ...
UroToday4d
Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.
Immune checkpoint blockade (ICB) is currently the standard of care for metastatic renal cell carcinoma (RCC), but treatment responses remain unpredictable. Aristolochic acid (AA), a prevalent ...
UroToday4d
Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer
Background. The association between patient demographics and CV events after ADT using real-world data was evaluated. In addition to encompassing >30 times more patients than all previous MACE studies ...